Luminate Medical vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dublin oncology device company developing at-home scalp cooling to prevent chemo hair loss; $22M YC and 8VC-backed with $15M Atlantic Bridge Series A pursuing FDA clearance for at-home oncology care model.
About
Luminate Medical is a Dublin, Ireland-based healthcare technology company developing patient-centered oncology care devices — most notably a next-generation scalp cooling system that prevents or reduces chemotherapy-induced hair loss (alopecia), one of the most psychologically distressing side effects of cancer treatment. Backed by Y Combinator, 8VC, and Atlantic Bridge with $22 million raised total including a $15 million Series A led by Atlantic Bridge in 2024 and a €6.4 million Irish Government grant in 2025, Luminate is pursuing FDA clearance for US market entry with first commercial revenues expected in 2025.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.